ENGLISH
 
简体中文
 
                 
 
  新闻类别
行业动态
预警分析
案件应对
预警工作
展会信息
行业新闻
企业新闻
 
 
行业动态
欧盟评估转基因贝莱斯芽孢杆菌菌株AR-112生产的内切-1,4-β-木聚糖酶的安全性
  • 作者:   来源:江苏汉光甜味剂有限公司    时间:2024/1/15    点击:13
2024年1月12日,欧盟食品安全局就一种食品酶内切-1,4-β-木聚糖酶(endo-1,4-β-xylanase)的安全性评价发布意见。
 
  据了解,这种食品酶是由转基因贝莱斯芽孢杆菌菌株AR-112生产的,旨在用于烘焙过程。
 
  经过评估,专家小组认为,在预期的使用条件下,不能排除通过饮食接触引起过敏反应的风险,但这种情况发生的可能性很低。根据所提供的数据,小组得出结论,该食品酶在预期的使用条件下不会引起安全问题。部分原文报道如下:
 
  The food enzyme endo-1,4-β-xylanase (4-β-d-xylan xylanohydrolase, EC 3.2.1.8) is produced with the genetically modified Bacillus velezensis strain AR-112 by AB Enzymes GmbH. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and its DNA. It is intended to be used in baking processes. Dietary exposure to the food enzyme–total organic solids (TOS) was estimated to be up to 0.024 mg TOS/kg body weight (bw) per day in European populations. As the production strain B. velezensis strain AR-112 meets the requirements for the qualified presumption of safety (QPS) approach to safety assessment and no issue of concern arose from the production process, no toxicological data are required. A search for the similarity of the amino acid sequence of the food enzyme to known allergens was made and no match was found. The Panel considered that, under the intended conditions of use, the risk of allergic reactions upon dietary exposure cannot be excluded, but the likelihood is low. based on the data provided, the Panel concluded that this food enzyme does not give rise to safety concerns under the intended conditions of use.